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The RIVUR Trial: Profile and Baseline Clinical
Associations of Children With Vesicoureteral Reflux
WHAT’S KNOWN ON THIS SUBJECT: The ideal management of
children with vesicoureteral reflux (VUR) remains a source of
debate. There is little evidence to support many of the current
management practices for children with VUR who have had 1 or 2
urinary tract infections.
WHAT THIS STUDY ADDS: Baseline associations, including
bladder and bowel dysfunction and imaging studies, from the
largest randomized, controlled trial conducted to date aimed at
assessing the value of antimicrobial prophylaxis in children with
urinary tract infection and VUR are presented.
abstract
BACKGROUND AND OBJECTIVE: Vesicoureteral reflux (VUR) is diagnosed
in ∼30% to 40% of children who have imaging studies after urinary tract
infections (UTIs). Our goal is to characterize children enrolled in the
Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR)
trial and to compare our study cohort with those from previously
published studies.
METHODS: RIVUR investigators from 19 pediatric sites in the United
States recruited 607 children with grade I through IV VUR. Children were
enrolled after a first or second UTI. This cross-sectional report of baseline
data includes extensive clinical, parental report, and imaging study
results.
RESULTS: RIVUR recruited 607 children (558 girls, 49 boys) with grade I
(11%), II (42%), III (38%), or IV (8%) reflux. The median age was 12 months,
and most children (91%) were enrolled after their first UTI. The UTI lead-
ing to enrollment was both febrile and symptomatic for 323 children,
febrile only in 197 children, and symptomatic only in 86. Renal involve-
ment at baseline as documented by a 99mTc dimercaptosuccinic acid
scan was uncommon with cortical defects identified in 89 (15%) chil-
dren. Bladder and bowel dysfunction was identified in 71 (56%) of 126
toilet-trained subjects assessed.
CONCLUSIONS: RIVUR is the largest prospective, randomized trial for
children with primary VUR to date, comparing prophylaxis with pla-
cebo. The study sample comprises patients from 19 pediatric clinical
sites in the United States, whose demographic and clinical character-
istics may differ from those of children enrolled in previous trials from
other countries. Pediatrics 2013;132:e34–e45
AUTHORS: Myra A. Carpenter, PhD,a Alejandro Hoberman,
MD, MPH,b Tej K. Mattoo, MD,c Ranjiv Mathews, MD,d Ron
Keren, MD, MPH,e Russell W. Chesney, MD,f Marva Moxey-
Mims, MD,g and Saul P. Greenfield, MD,h for the RIVUR Trial
Investigators
aDepartment of Biostatistics, The University of North Carolina,
Chapel Hill, North Carolina; bDepartment of Pediatrics, Children’s
Hospital of Pittsburgh, Pittsburgh, Pennsylvania; cDepartment of
Pediatrics, Children’s Hospital of Michigan, Detroit, Michigan;
dDepartment of Urology, Johns Hopkins School of Medicine,
Baltimore, Maryland; eDepartment of Pediatrics, Children’s
Hospital of Philadelphia, Philadelphia, Pennsylvania; fDepartment
of Pediatrics, University of Tennessee Health Science Center,
Memphis, Tennessee; gNational Institute of Diabetes and Digestive
and Kidney Diseases, National Institutes of Health, Bethesda,
Maryland; and hDepartment of Pediatric Urology, Women &
Children’s Hospital of Buffalo, Buffalo, New York
KEY WORDS
vesicoureteral reflux (VUR), urinary tract infections, renal
scarring, clinical research/trials
ABBREVIATIONS
BBD—bladder and bowel dysfunction
DMSA—99mTc dimercaptosuccinic acid





Dr Carpenter directs the RIVUR Data Coordinating Center and
carried out the statistical analyses, participated in
conceptualization and design of the study, and drafted the initial
abstract and Methods and Results sections; Dr Hoberman is
a core clinical site investigator and was responsible for
enrolling study participants, participated in conceptualization
and design of the study, and drafted the initial Introduction
section; Drs Mattoo and Mathews are core clinical site
investigators and were responsible for enrolling study
participants, and participated in conceptualization and design
of the study; Dr Keren is a core clinical site investigator and was
responsible for enrolling study participants, participated in the
conceptualization and design of the study, and prepared the
initial draft of Table 4; Dr Chesney is chair of the Steering
Committee and he participated in the conceptualization and
design of the study; Dr Moxey-Mims conceptualized and
participated in the design of the study; Dr Greenfield is a core
clinical site investigator and was responsible for enrolling study
participants, drafted the initial Discussion and Conclusions
sections, and participated in the conceptualization and design of
the study; and all authors reviewed and revised the manuscript,
and approved the final manuscript as submitted.
(Continued on last page)
e34 CARPENTER et al
Approximately one-third of childrenwho
have a urinary tract infection (UTI) have
vesicoureteral reflux (VUR), which is
associated with a higher risk of renal
scarring.1 However, VUR is neither nec-
essary nor sufficient for renal damage
to occur; scars are noted in children
whodo not have VUR, andmany children
with higher-grade VUR never develop
scars. The Randomized Intervention for
Children with Vesicoureteral Reflux
(RIVUR) trial was designed to address
limitations of previous studies, mostly
the lack of a placebo or observation
arm, and provide higher-quality evi-
dence about the efficacy of antimicrobial
prophylaxis for preventing recurrent
UTI in children with VUR.2–4
Recent trials evaluated the efficacy of
antimicrobial prophylaxis among chil-
drenwithUTI andVURandshowedeither
no or slight decrease in the incidence of
recurrent UTI and renal scarring.5 De-
spite methodologic limitations of these
trials addressed in recent editorials5,6
and the trials’ lack of evaluation of the
impact of bladder and bowel dysfunc-
tion (BBD) on recurrent UTI, recent man-
agement guidelines have used these
data to question the role of antimicrobial
prophylaxis or even the need to obtain
imaging studies to detect VUR in chil-
dren after an initial episode of UTI.7–10
This report provides cross-sectional
baseline data from the ongoing RIVUR
trial at 19 clinical sites in the United
States. We provide demographic and
clinical characteristics of RIVUR par-
ticipants as well as study design
parameters that enable placement of
our sample in context with previous
US and international cohort studies of
children with UTI and VUR.
METHODS
Study Design
The RIVUR trial is a randomized, double-
blind, placebo-controlled trial of prophy-
lactic trimethoprim-sulfamethoxazole
in children with VUR. The rationale and
trial design have been described pre-
viously.2–4 Briefly, we enrolled infants
and children aged 2 to 71 months with
grade I through IV VUR after a first or
second febrile or symptomatic UTI. Pri-
mary exclusion criteria included index
UTI diagnosis .112 days before en-
rollment, comorbid urologic anomalies
(Society of Fetal Ultrasonography grade
4 hydronephrosis with renal parenchyma
atrophy, ureterocele, urethral valve, sol-
itary kidney, profoundly small [.2 SD
below the mean] kidney, multicystic
dysplastic kidney, neurogenic bladder,
pelvic kidney, or fused kidney), contra-
indications for use of trimethoprim-
sulfamethoxazole, and selected other
medical conditions. Children are fol-
lowed for 2 years to ascertain recur-
rent febrile or symptomatic UTI, renal
scarring, prophylaxis failure, antimi-
crobial resistance, medication adher-
ence, and quality of life measures. A
Data and Safety Monitoring Board and
institutional review boards governing
each site approved the protocol, and
parents or legal guardians provided
written informed consent for each par-
ticipant before any study procedures.
Data Collection
Screening and enrollment of children
into the study took place from June
2007 through May 2011. Screening data
are incomplete because the study did
not begin data capture for screening
until November 2007. Baseline data
collection included medical history,
physical examination, and a parent-
administered quality-of-life question-
naire. In toilet-trained children, a par-
ent-administered questionnaire that
was based on a modified version of the
scoring system reported by Farhat and
colleagues11–13 (see Appendix 1) cap-
tured urination and bowel movement
characteristics. Data were also col-
lected on 5 of the 6 conditions that
define chronic constipation according
to the Paris Consensus on Childhood
Constipation Terminology Group14 in-
cluding frequency of bowel movements
as,3 per week,.1 fecal incontinence
event per week, passing of large stool
that obstructed the toilet, retentive
posture and behavior, and pain during
defecation. Chronic constipation was
defined by the presence of $2 con-
ditions being met during the preceding
2 months.
Child’s race and ethnicity were self-
reported by parents; mixed race is
analyzed as nonwhite. The index UTI
was the child’s first or second UTI that
was used to qualify the child for study
enrollment. To be eligible, the index
UTI met stringent criteria4 including
documented evidence of (1) pyuria on
urinalysis, (2) culture-proven infection,
and (3) fever ($38°C) or symptoms
within 24 hours of urine collection. We
required a urine culture yielding a sin-
gle organism that was neither lacto-
bacillus nor candida, at $5 3 104
colony forming units per milliliter for
catheterized or suprapubic aspira-
tion urine specimens or $105 colony
forming units per milliliter for clean
voided specimens. Qualifying symptoms
for the index UTI included suprapubic,
abdominal, or flank pain or tenderness;
urinary urgency, frequency or hesi-
tancy; dysuria; and malodorous urine
or in infants #4 months of age, failure
to thrive, dehydration, or hypothermia.
Blood pressure, height (or length), and
weight were measured using available
equipment and local procedures. Age is
reported at the time of randomization.
Radiographicprocedures includedrenal
ultrasound, voiding cystourethrogram
(VCUG), and 99mTc dimercaptosuccinic
acid (DMSA) scintigraphy. Renal ultra-
sound and VCUG were completed within
112 days after the index UTI and before
enrollment; most DMSA scans were
obtained within 2 weeks of enrollment
but no more than 112 days after the
index UTI. Although eligibility was based
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on local reports for ultrasound and
VCUG, images were also assessed by 2
pediatric radiologists using a standard-
ized reading protocol.4,15 We report
these data from the central radiologists.
VUR was graded according to the sys-
tem of the International Reflux Study
Group.16 Worst VUR was defined as the
highest grade of reflux17 from either the
left or right side. Similarly, 2 pediatric
nuclear medicine physicians centrally
interpreted DMSA scans for the pres-
ence of cortical defects.4,18 Scans with
decreased uptake of DMSA tracer were
differentiated by (1) retention of renal
contours (consistent with acute pyelo-
nephritis) or (2) loss of contours or
cortical thinning (consistent with renal
scarring) as demonstrated by Majd and
Rushton.19 The extent of cortical defects
was assessed semiquantitatively by di-
viding the renal cortex into 12 segments
and counting the number of renal pa-
renchyma segments affected.4,18 Sever-
ity was determined by the number of
segments affected: mild (1–2), moder-
ate (3–4), or severe ($5) or as global
atrophy characterized by a diffusely
scarred and shrunken kidney.
Statistical Analyses
We used Centers for Disease Control
and Prevention growth standards for
children $2 years of age and World
Health Organization standards for
children ,2 years of age to convert
height and weight measurements to z
scores and percentiles.20–22 We calcu-
lated blood pressure percentiles for
gender, age, and height for children$1
year of age using regression models
specified in the fourth report from the
National High Blood Pressure Educa-
tion Program Working Group on Chil-
dren and Adolescents.23 For children
,1 year of age, we dichotomized blood
pressure at the 90th percentile based
on cut points from the Second Task
Force.24 VUR and renal cortical defects
are reported if present on either kidney,
with severity reported as the worst of
both kidneys. The presence of BBD was
defined by a score of $6 for females
and $9 for males, using the scoring
weights from Farhat and colleagues.11
BBD and chronic constipation were
evaluated only for children who were
toilet-trained for both urine and bowel
movements.
With the exception of age, for which
a Kruskal-Wallis test was performed
due to the skewed distribution, com-
parison of continuous characteristics
by VUR grade was by analysis of vari-
ance; x2 test was used for compar-
isons of categorical variables unless
an expected cell count of ,5 was
present in which case Fisher’s exact
test was used. SAS version 9.2 software
(SAS Institute, Cary, NC) was used for
all statistical analyses.
RESULTS
Screeningdata are incomplete because
of delayed onset of screening data
capturebut include492 (81%) of the 607
enrolled participants. Of 10 753 chil-
dren with screening data available,
only 12% met all eligibility criteria. Al-
most 60% of screened children did not
meet study criteria for a first or second
UTI; more than half of the screened
children either did not have VCUG
results (24%) or did not have VUR
(30%) or had grade V VUR (1%); 14%
failed other eligibility criteria. Of the
1311 eligible screened children, 62%
refused and 38% were enrolled. Those
eligible but not enrolled did not differ
from those enrolled in the distributions
of gender, race, or ethnicity (data not
shown).
The 19 clinical sites (Table 1) enrolled
558 girls and 49 boys (18 or 37%, cir-
cumcised). Most had grade II (42%) or
grade III (38%) VUR; 11% had grade I
(including 7 children with no VUR
based on the central assessment) and
8% had grade IV (including 1 child with
gradeVbasedon the central assessment).
The distribution of VUR grade by gen-
der is provided in Table 2. VCUGs were
not available for central assessment
for 5 children. Approximately half of the
children had unilateral VUR and half
had bilateral VUR. Demographic and
clinical characteristics of participants
in the RIVUR study, overall and by VUR
grade, are summarized in Table 3.
Children were aged 2 to 71 months,
with a median age of 12 months. White
race predominated (82% of girls and
65% of boys); 40 (7%) children were
mixed race, 27 (5%) were African
American, and 48 (8%) reported other
races. Race was not recorded for 10
children. Seventy-seven children (13%)
were of Hispanic ethnicity.
Of the 607 children enrolled, 554 (91%)
were recruited after their first UTI; 53
(9%) had a second UTI before enroll-
ment. The index UTI was febrile and
symptomatic in 323 (53%) of the chil-
dren, febrile only in 197 (32%), symp-
tomatic only in 86 (14%), and with fever
and symptoms outside of the 24-hour
window of urine collection for 1 child.
Escherichia coli was the predominant
infective organism in 538 (89%) index
UTIs with Klebsiella pneumoniae (n =
16, 3%) and Proteus mirabilis (n = 14,
2%) the next most frequent. Children
with index UTIs from non–E coli infec-
tions were more likely to have a higher
grade of VUR (14 of 66 [21%] vs 35 of
535 [7%] had grade IV VUR, P = .0003),
a nonfebrile index UTI (16 of 68 [24%] vs
71 of 538 [13%], P = .02), and a higher
proportion of loss of renal contour
(5 of 61 [8%] vs 16 of 520 [3%], P = .06)
than children with E coli infections.
Twenty-one (4%)of the582childrenwith
DMSA scan results had decreased
tracer uptakewith loss of renal contour
(scarring) at baseline (Table 4) with
severity classified as mild (n = 1),
moderate (n = 5), severe (n = 6), or
global atrophy (n = 9). Loss of renal
contour was noted in 17 of 535 (3%)
girls and in 4 of 47 boys (9%) assessed.
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Decreased tracer uptake in conjunc-
tion with retention of renal contour
(acute pyelonephritis) was identified in
71 (12%) children, including 3 children
who also had loss of contour. In 100
children, the DMSA scan was per-
formed within 30 days of the index UTI;
timing of the scan was not statistically
associated with the index UTI being
febrile, but there was a nonsignificant
higher proportion of loss of renal
contour present in scans performed
$31 days after the index UTI (20 of 21
children with loss of renal contour had
the DMSA scan $1 month after the
index UTI, P = .23). Twenty-seven per-
cent of children with decreased uptake
associated with no loss of renal con-
tour underwent the DMSA scan within
30 days of the index UTI diagnosis.
Compared with children with normal
DMSA scans, more of those having any
cortical defect were aged$12 months
at enrollment (62% vs 49%, P = .03),
had a febrile index UTI (93% vs 84%, P =
.02), had a UTI before the index UTI (16%
vs 7%, P = .007), and had grade IV VUR
(17% vs 7%, P = .02; Cochran-Armitage
trend test P = .03).
BBD was evident in 71 (56%) of 126
toilet-trained children, generally
reflecting a mixture of both bladder
and bowel symptoms; the assessment
was not completed for 8 toilet-trained
children. All 71 children with BBD were
girls (only 2 boys were both toilet-
trained and completed the BBD assess-
ment), andBBDwas not associatedwith
race, ethnicity, VUR grade, or presence
of any renal cortical defect in this
small subgroup. Sixteen toilet-trained
children met criteria for chronic con-
stipation, of whom 14 also met criteria
for BBD.
Boys were significantly younger than
girls at baseline; 84%ofmales vs 46%of
females were,12 months of age (P,
.0001). Thirteen of 41 boys ,1 year of
age were circumcised (32%) compared
with 5 (63%) of 8 older boys. Of 17
Hispanic boys, 14 were,1 year of age
and uncircumcised; of the 3 older His-
panic boys, 1 was circumcised. Six boys
had grade IV VUR, of whom 2 were
circumcised. Among the male children,
71% of index UTIs were E coli, and 71%
of these boys were uncircumcised
compared with 43% of those with non–
E coli infections.
Table 5 profiles children enrolled in
RIVUR relative to cohort studies of VUR
in children following UTI that were
considered in the American Academy
of Pediatrics technical report.25 Al-
though design and patient character-
istics vary across studies, children
with intermediate grades of VUR (ie,
grades II and III) predominate.
DISCUSSION
The distribution of RIVUR study partic-
ipants by gender and within racial and
ethnic groups is consistent with pre-
vious studies in the United States. In
American cohorts of children with VUR
identified after UTI, boys represent
TABLE 1 RIVUR Clinical Sites
Hospital City, State Principal Investigator Recruitment Sites Number Randomized
Female Male Overall
Akron Children’s Hospital Akron, OH Dan McMahon, MD PCP, ED, UP, NP, IS 14 0 14
Johns Hopkins School of Medicine Baltimore, MD Ranjiv Mathews, MD PCP, UP, NP, IS 49 7 56
University of Alabama Birmingham Birmingham, AL Sahar Fathallah, MD PCP, UP, NP 3 1 4
Children’s Hospital of Boston Boston, MA Caleb Nelson, MD PCP, ED, UP, NP 25 5 30
Women and Children’s Hospital of Buffalo Buffalo, NY Saul Greenfield, MD PCP, ED, UP, IS 46 2 48
Ann & Robert H. Lurie Children’s Hospital
of Chicago
Chicago, IL Earl Cheng, MD PCP, ED, UP, NP, IS 13 2 15
Cincinnati Children’s Hospital Cincinnati, OH William R. DeFoor, Jr., MD PCP, UP, IS 9 0 9
Children’s Hospital of Michigan Detroit, MI Tej Mattoo, MD IS 57 3 60
Penn State Hershey Medical Center Hershey, PA Ross Decter, MD PCP, ED, UP, NP, IS 2 0 2
Texas Children’s Hospital Houston, TX Eileen Brewer, MD UP, NP 7 2 9
Children’s Mercy Hospital Kansas City, MO Mary Ann Queen, MD UP, NP, IS 6 0 6
University of Wisconsin Children’s Hospital Madison, WI Sharon Bartosh, MD PCP, ED, UP, NP, IS 2 0 2
University of Oklahoma Oklahoma City, OK Brad Kropp, MD UP 36 1 37
Children’s Hospital of Philadelphia Philadelphia, PA Ron Keren, MD PCP, ED, UP, IS 60 6 66
Children’s Hospital of Pittsburgh Pittsburgh, PA Alejandro Hoberman, MD PCP, ED, UP, IS 146 8 154
Oregon Health & Science University Portland, OR Steven Skoog, MD PCP, ED, UP, IS 28 5 33
Children’s National Medical Center Washington, DC H. Gil Rushton, MD PCP, ED, UP, NP, IS 35 5 40
Alfred I. duPont Hospital for Children Wilmington, DE Amy Renwick, MD PCP, UP, IS 7 1 8
Wake Forest University Baptist Medical Center Winston-Salem, NC Milan Nadkarni, MD PCP, ED, UP, NP, IS 13 1 14
ED, emergency department; IP, inpatient service; NP, nephrology practice; PCP, primary care practice; UP, urology practice.
TABLE 2 Distribution of VUR Grade by
Gender, n (%)
Worst VUR Gradea Girls Boys Overall
I 65 (12) 3 (6) 68 (11)
II 232 (42) 22 (45) 254 (42)
III 212 (38) 18 (37) 230 (38)
IV 44 (8) 6 (12) 50 (8)
a Seven children with a central assessment of ‘no VUR’are
included in grade I and one child with a central assessment
of grade V is included in grade IV.
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a minority,26,27 as they do in VCUG-based
studies.28,29 This was also reflected in
the RIVUR cohort. When race is reported
in studies of VUR in the United States,
white race predominates.28–33 Approxi-
mately 80% of children in the RIVUR
study were white and 5% were African
American. Thirteen percent of partic-
ipants self-reported as being of His-
panic ethnicity. Low rates of neonatal
circumcision among Hispanics may
account for uncircumcised Hispanic
males representing approximately one-
third of all male subjects in the RIVUR
study.30,34 More than 90% of children
with VUR in 2 previous American series
had grade III or less reflux.26,27 Simi-
larly, in the RIVUR cohort, 92% of chil-
dren had grades III or less, the majority
being grade II (42%) or grade III (38%).
Grade IV accounted for only 8% of
children. While children with Grade
V VURwere excluded in the RIVUR study,
this grade of VUR is seen in a small
fraction of children that have VUR iden-
tified after a UTI.35,36 More than 1 in 5
children in the RIVUR study were toilet
trained, and .50% of these children
exhibited BBD documented using the
Farhat instrument11 modified for US
vernacular. More children in the trial will
experience BBD during the 2-year ob-
servation period. This is a particularly












Age in mo, median (IQR) 12 (6–31) 17 (11–44) 12.5 (6–32) 11 (5–27) 8 (4–18) ,.001
Female gender 558 (92%) 65 (96%) 232 (91%) 212 (92%) 44 (88%) NS
Nonwhite race 115 (19%) 14 (21%) 51 (20%) 45 (20%) 4 (9%) NS
Height-for-age percentile 56 6 31.6 60 6 30.1 54 6 31.4 54 6 32.5 62 6 31.5 NS
Weight-for-age percentile 61 6 28.0 65 6 27.1 62 6 27.5 59 6 29.0 63 6 26.4 NS
Blood pressure $90th percentile
Systolic 155 (31%) 14 (26%) 61 (29%) 64 (34%) 14 (34%) NS
Diastolic 186 (38%) 22 (41%) 81 (39%) 69 (38%) 13 (32%) NS
Hematocrit (%) 35 6 3.0 36 6 2.4 35 6 3.1 35 6 3.1 33 63 .0 .001
Platelet count (3 10⁹/L) 385 6 121.6 371 6 131.0 382 6 108.1 384 6 117.7 424 6 182.6 NS
Toilet trained for urine and bowel 134 (22%) 22 (33%) 62 (25%) 39 (17%) 11 (22%) .032
BBDb 71 (56%) 10 (50%) 34 (57%) 23 (64%) 4 (40%) NS
Decreased 99mTc DMSA uptake with loss of renal contours or
cortical thinningc
21 (4%) 2 (3%) 4 (2%) 9 (4%) 6 (13%) .008
Decreased 99mTc DMSA uptake with retention of renal contoursc 71 (12%) 6 (9%) 31 (12%) 24 (10%) 10 (20%) NS
Ureter duplication 26 (4%) 0 (0%) 9 (4%) 11 (5%) 6 (12%) .017
Hydronephrosisd 32 (5%) 4 (6%) 5 (2%) 12 (5%) 11 (22%) ,.001
Statistics are reported as number (%) or mean6 SD unless otherwise indicated; the VCUGs for 5 participants were not available for centralized evaluation. IQR, interquartile range; NS, not
significant.
a NS P. .10; tests for association between characteristic and VUR grade based on Kruskal-Wallis test for age, analysis of variance for other continuous variables, and x2 or Fisher’s exact test
for categorical variables.
b Assessed among 126 toilet-trained children; based on modification of the Dysfunctional Voiding Scoring System.11
c Worst of left and right kidney; decreased uptake with loss of renal contour or cortical thinning is consistent with renal scarring; decreased update with retention of renal contours is
consistent with acute pyelonephritis.
d Hydronephrosis less than Society of Fetal Ultrasonography grade 4.
TABLE 4 Participant Characteristics by DMSA Scan Results
Characteristics Decreased Uptake With
Loss of Contoursa (n = 21)
Decreased Uptake With
Contour Retentiona (n = 71)
Any Cortical Defect
Yes (n = 89) No (n = 493) Pb
DMSA timingc
,31 d 1 (5%) 19 (27%) 20 (22%) 78 (16%) NS
$31 d 20 (95%) 52 (73%) 69 (78%) 415 (84%)
Age (mo)
,12 8 (38%) 27 (38%) 34 (38%) 250 (51%) 0.030
$ 12 13 (62%) 44 (62%) 55 (62%) 243 (49%)
Gender
Females 17 (81%) 69 (97%) 84 (94%) 451 (91%) NS
Males 4 (19%) 2 (3%) 5 (6%) 42 (9%)
Index UTI
Febrile 20 (95%) 66 (93%) 83 (93%) 415 (84%) 0.025
Not febrile 1 (5%) 5 (7%) 6 (7%) 78 (16%)
Previous UTI
None 17 (81%) 61 (86%) 75 (84%) 458 (93%) 0.007
1 4 (19%) 10 (14%) 14 (16%) 35 (7%)
VUR grade
I 2 (10%) 6 (8%) 8 (9%) 55 (11%) 0.017
II 4 (19%) 31 (44%) 34 (38%) 211 (43%)
III 9 (43%) 24 (34%) 32 (36%) 189 (39%)
IV 6 (29%) 10 (14%) 15 (17%) 33 (7%)
NS, not significant.
a Includes 3 children who had decreased DMSA uptake with both loss of contour or cortical thinning (consistent with renal
scarring) and retention of contour (consistent with acute pyelonephritis) based on DMSA scan.
b NS: P value. .10; tests for association between characteristic and any cortical defect based on x2 or Fisher’s exact test.
c Number of days between the Index UTI diagnosis and DMSA scan.
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interesting subgroup of children, given
the known increased likelihood of
breakthrough UTIs in children with BBD
receiving antimicrobial prophylaxis.37,38
An established renal scar as defined by
decreased uptake of tracer in con-
junction with loss of renal contour or
cortical thinning at baseline was in-
frequent in the RIVUR cohort (4%),
a proportion substantially lower than
previously reported.39,40 Possible ex-
planations include that participants
had experienced only 1 or 2 UTIs, the
acceptance of children into the trial
after a nonfebrile (although symptom-
atic) UTI, a relatively low proportion of
children with Grade IV VUR, scans were
obtained relatively close to the time of
the index UTI so defects consistent with
scars may not have had sufficient time
to become visible, and adjudication
review by 2 pediatric nuclear medicine
specialists. Scarring characterized by
decreased tracer uptake with loss of
cortical margin can be due to either an
episode of acute pyelonephritis more
than a few weeks before scanning
or congenital dysplasia. Decreased
uptake of tracer with retention of renal
contours, consistent with acute pyelo-
nephritis, was more common (12%),
and most were after febrile index UTIs.
Interestingly, more than half of those
with decreased uptake and contour
retention had grades I and II VUR. A
number of those patients with acute
pyelonephritis will be left with perma-
nent scars. Renal scarring represents
a secondary outcome of the RIVUR
study, and it remains to be seen how
many additional scars will be identified
at completion of the 2-year observation
period, but baseline presence of any
cortical defect is consistent with the
more recent studies of children after
first UTI.41
Consistent with previously reported
results of renal ultrasound performed
in children after UTI,1 most were
interpreted as normal; hydronephrosis
was rarely identified (5%), and in most
instances (23/32, or 72%), it was as-
sociated with dilated VUR (grades III
and IV). Conversely, and as indicated by
others,42–44 ultrasonography was not
particularly useful in identifying di-
lated VUR. Among children with grade
III or IV VUR, hydronephrosis was di-
agnosed in only 5% and 22% of chil-
dren, respectively, a low sensitivity
consistent with previous reports.1 This
is particularly relevant given recently
published UTI guidelines7–10,25 that
generally recommend not performing
a VCUG after an initial febrile UTI unless
ultrasonographic findings are abnor-
mal or other risk factors are present.
Although there appears to be reason-
ably high agreement between pediatric
radiologists in the grading of VUR,15
some discrepancy is expected. RIVUR
eligibility was based on VUR grade
assigned at the enrollment site (local
reading), whereas the results being
reported herein are from the stan-
dardized and adjudicated grades deter-
mined by 2 RIVUR radiologists (central
reading). Differences in interpretation of
the scans are evident as our data in-
clude 7 children with no VUR and 1 child
with grade V VUR based on the central
assessment but whowere considered to
have VUR grade I through IV based on the
local report.
In recently published series of children
with VUR from Europe and Australia,
boyswith VUR accounted for 31% to 50%
of participants, almost all of whomwere
uncircumcised.39,45–48 In contrast, 92%
of subjects in the RIVUR studywere girls.
Of all subjects enrolled, ∼50% were
aged ,1 year, particularly male sub-
jects (84%), a third of whom were cir-
cumcised. A more routine practice of
circumcision may explain the relative
paucity of boys presenting with febrile
UTI and VUR in the US population.
E coli was the most frequently isolated
organism from the index UTI. According
to some, non–E coli UTIs have been
associated with more clinically signifi-
cant VUR.10 Our data suggest that there
may be a correlation between non–E
coli index UTI and higher reflux grade
and a higher proportion of childrenwith
loss of renal contour, despite a lower
rate of febrile index UTI.
Retrospective or prospective studies of
children with primary VUR all differ in
the demographics of the population
studied. They reflect a variety of study
designs with differences in inclusion
and exclusion criteria (eg, number of
previous UTIs and grade of VUR) and
withdifferences innumbersof patients,
patient age, health care delivery sys-
tems, recruitment settings, sociocul-
tural characteristics (including those
driven by geographic location), and
race and ethnic distributions that
can influence the results obtained, re-
ducing the ability to generalize to all
populations. These venue and demo-
graphic differences may explain dispa-
rate outcomes across studies. Although
screening data are limited and selection
bias can never be ruled out completely,
the RIVUR trial enrolled a large number
of children from a variety of clinical
settings reflecting the medical and cul-
tural milieu in the United States from
2007 to 2011.
CONCLUSIONS
The evaluation and management of
children with UTI and VUR remains
controversial and unsettled. The RIVUR
study is the largest prospective, ran-
domized trial for children with primary
VUR comparing prophylaxis with pla-
cebo to date. It provides a large patient
population from the United States, the
demographic composition of which
may differ from those reported else-
where. In addition, because of the use
of adjudicated radiographic interpre-
tations, stringent definition of UTI,
consistent assessment of BBD, and
close clinical monitoring, it is antici-
pated that the outcomes will enable
e40 CARPENTER et al
improved evidence-based evaluation and
treatment algorithms.
ACKNOWLEDGMENTS
We thank the RIVUR participants, their
families and participating physicians,
investigators, and staffs for making
this research possible. Principal inves-
tigators of the RIVUR clinical sites
are Sharon M. Bartosh, MD (University
of Wisconsin Hospital and Clinics,
Madison, WI); Eileen Brewer, MD (Texas
Children’s Hospital, Houston, TX); Earl Y.
Cheng, MD (Ann& Robert H. Lurie Child-
ren’s Hospital, Chicago, IL); Ross Decter,
MD (Penn State Milton S. Hershey
Medical Center, Hershey, PA); William
Robert DeFoor, Jr, MD, MPH (Cincinnati
Children’s Hospital, Cincinnati, OH);
Sahar Fathallah-Shaykh, MD (Univer-
sity of Alabama at Birmingham School
of Medicine, Birmingham, AL); Saul P.
Greenfield, MD (Women and Children’s
Hospital of Buffalo, Buffalo, NY); Alejandro
Hoberman, MD (Children’s Hospital
of Pittsburgh, Pittsburgh, PA); Ron
Keren, MD, MPH (Children’s Hospital of
Philadelphia, Philadelphia, PA); Bradley
P. Kropp, MD, FAAP, FACS (University
of Oklahoma Health Sciences Center,
Oklahoma City, OK); Ranjiv Mathews,
MD (Johns Hopkins School of Medicine,
Baltimore, MD); Tej K. Mattoo, MD, DCH,
FRCP (UK) (Wayne State University
School of Medicine, Detroit, MI); Daniel
R. McMahon, MD (Akron Children’s Hos-
pital, Akron, OH); Milan Nadkarni, MD
(Wake Forest University Baptist Medi-
cal Center, Winston-Salem, NC); Caleb P.
Nelson, MD, MPH (Boston Children’s
Hospital, Boston, MA); Mary Ann Queen,
MD (Children’s Mercy Hospital of Kan-
sas City, Kansas City, MO); Amy Renwick,
MD (Alfred I. duPont Hospital for Chil-
dren, Wilmington, DE); H. Gil Rushton,
Jr., MD, FAAP (Children’s National Med-
ical Center, Washington, DC); Steven J.
Skoog, MD, FACS, FAAP (Oregon Health
and Science University, Portland, OR);
Ming-Hsien Wang, MD (Johns Hopkins
School of Medicine, Baltimore, MD).
REFERENCES
1. Hoberman A, Charron M, Hickey RW, Baskin
M, Kearney DH, Wald ER. Imaging studies
after a first febrile urinary tract infection
in young children. N Engl J Med. 2003;348
(3):195–202
2. Chesney RW, Carpenter MA, Moxey-Mims M,
et al; members of the RIVUR Steering Com-
mittee. Randomized Intervention for Chil-
dren With Vesicoureteral Reflux (RIVUR):
background commentary of RIVUR inves-
tigators. Pediatrics. 2008;122(suppl 5):S233–
S239
3. Keren R. Pediatrics. RIVUR trial. In-
troduction. Pediatrics. 2008;122(suppl 5):
S231–S232
4. Keren R, Carpenter MA, Hoberman A, et al.
Rationale and design issues of the Ran-
domized Intervention for Children With
Vesicoureteral Reflux (RIVUR) study. Pedi-
atrics. 2008;122(suppl 5):S240–S250
5. Hoberman A, Keren R. Antimicrobial pro-
phylaxis for urinary tract infection in
children. N Engl J Med. 2009;361(18):1804–
1806
6. Wan J, Skoog SJ, Hulbert WC, et al; Execu-
tive Committee, Section on Urology, Amer-
ican Academy of Pediatrics. Section on
Urology response to new Guidelines for the
Diagnosis and Management of UTI. Pediat-
rics. 2012;129(4). Available at: www.pediat-
rics.org/cgi/content/full/129/4/e1051
7. Ammenti A, Cataldi L, Chimenz R, et al;
Italian Society of Pediatric Nephrology. Fe-
brile urinary tract infections in young
children: recommendations for the di-
agnosis, treatment and follow-up. Acta
Paediatr. 2012;101(5):451–457
8. Riccabona M, Avni FE, Blickman JG, et al.
Imaging recommendations in paediatric
uroradiology: minutes of the ESPR work-
group session on urinary tract infection,
fetal hydronephrosis, urinary tract ultra-
sonography and voiding cystourethrog-
raphy, Barcelona, Spain, June 2007. Pediatr
Radiol. 2008;38(2):138–145
9. Roberts KB; Subcommittee on Urinary Tract
Infection, Steering Committee on Quality
Improvement and Management. Urinary
tract infection: clinical practice guideline
for the diagnosis and management of the
initial UTI in febrile infants and children 2
to 24 months. Pediatrics. 2011;128(3):595–
610
10. Mori R, Lakhanpaul M, Verrier-Jones K. Di-
agnosis and management of urinary tract
infection in children: summary of NICE
guidance. BMJ. 2007;335(7616):395–397
11. Farhat W, Bägli DJ, Capolicchio G, et al. The
dysfunctional voiding scoring system:
quantitative standardization of dysfunc-
tional voiding symptoms in children. J Urol.
2000;164(3 pt 2):1011–1015
12. Farhat W, McLorie GA, O’Reilly S, Khoury A,
Bägli DJ. Reliability of the pediatric dys-
functional voiding symptom score in moni-
toring response to behavioral modification.
Can J Urol. 2001;8(6):1401–1405
13. Shaikh N, Hoberman A, Wise B, et al. Dys-
functional elimination syndrome: is it related
to urinary tract infection or vesicoureteral
reflux diagnosed early in life? Pediatrics.
2003;112(5):1134–1137
14. Benninga M, Candy DC, Catto-Smith AG,
et al; The Paris Consensus on Childhood
Constipation Terminology (PACCT) Group.
The Paris Consensus on Childhood Con-
stipation Terminology (PACCT) Group. J
Pediatr Gastroenterol Nutr. 2005;40(3):273–
275
15. Greenfield SP, Carpenter MA, Chesney RW,
Zerin JM, Chow J. The RIVUR voiding cys-
tourethrogram pilot study: experience with
radiologic reading concordance. J Urol.
2012;188(4 suppl):1608–1612
16. Medical versus surgical treatment of pri-
mary vesicoureteral reflux: report of the
International Reflux Study Committee. Pe-
diatrics. 1981;67(3):392–400
17. Lebowitz RL, Olbing H, Parkkulainen KV,
Smellie JM, Tamminen-Möbius TE; In-
ternational Reflux Study in Children. In-
ternational system of radiographic grading
of vesicoureteric reflux. Pediatr Radiol.
1985;15(2):105–109
18. Ziessman HA, Majd M. Importance of meth-
odology on (99m)technetium dimercapto-
succinic acid scintigraphic image quality:
imaging pilot study for RIVUR (Randomized
Intervention for Children With Vesicoureteral
Reflux) multicenter investigation. J Urol.
2009;182(1):272–279
19. Majd M, Rushton HG. Renal cortical scin-
tigraphy in the diagnosis of acute pyelo-
nephritis. Semin Nucl Med. 1992;22(2):
98–111
ARTICLE
PEDIATRICS Volume 132, Number 1, July 2013 e41
20. WHO Multicentre Growth Reference Study
Group. WHO Child Growth Standards based
on length/height, weight and age. Acta
Paediatr Suppl. 2006;450:76–85
21. Grummer-Strawn LM, Reinold CM, Krebs
NF, National Center for Chronic Disease
Prevention and Health Promotion. Use of
World Health Organization and CDC
Growth Charts for Children Aged 0–59
Months in the United States. Atlanta, GA:
Deptartment of Health and Human Serv-
ices, Centers for Disease Control and
Prevention; 2010
22. World Health Organization. WHO Anthro
(version 3.2.2, January 2011) and macros.
Available at: www.who.int/childgrowth/soft-
ware/en. Accessed September 2, 2012
23. The fourth report on the diagnosis, eval-
uation, and treatment of high blood
pressure in children and adolescents.
Pediatrics. 2004;114(2 suppl 4th report):
555–576
24. Report of the Second Task Force on Blood
Pressure Control in Children—1987. Task
Force on Blood Pressure Control in Chil-
dren. National Heart, Lung, and Blood In-
stitute, Bethesda, Maryland. Pediatrics.
1987;79(1):1–25
25. Finnell SM, Carroll AE, Downs SM; Sub-
committee on Urinary Tract Infection.
Technical report—diagnosis and manage-
ment of an initial UTI in febrile infants and
young children. Pediatrics. 2011;128(3).
Available at: www.pediatrics.org/cgi/con-
tent/full/128/3/e749
26. Greenfield SP, Ng M, Wan J. Experience with
vesicoureteral reflux in children: clinical
characteristics. J Urol. 1997;158(2):574–577
27. Skoog SJ, Belman AB, Majd M. A non-
surgical approach to the management of
primary vesicoureteral reflux. J Urol. 1987;
138(4 pt 2):941–946
28. Chand DH, Rhoades T, Poe SA, Kraus S,
Strife CF. Incidence and severity of ves-
icoureteral reflux in children related to
age, gender, race and diagnosis. J Urol.
2003;170(4 pt 2):1548–1550
29. Melhem RE, Harpen MD. Ethnic factors in
the variability of primary vesico-ureteral
reflux with age. Pediatr Radiol. 1997;27(9):
750–751
30. Arant BS Jr. Medical management of mild
and moderate vesicoureteral reflux: fol-
lowup studies of infants and young children.
A preliminary report of the Southwest Pe-
diatric Nephrology Study Group. J Urol. 1992;
148(5 Pt 2):1683–1687
31. Askari A, Belman AB. Vesicoureteral reflux
in black girls. J Urol. 1982;127(4):747–748
32. Horowitz M, Gershbein AB, Glassberg KI.
Vesicoureteral reflux in infants with prenatal
hydronephrosis confirmed at birth: racial
differences. J Urol. 1999;161(1):248–250
33. Skoog SJ, Belman AB. Primary vesicoure-
teral reflux in the black child. Pediatrics.
1991;87(4):538–543
34. West W, Venugopal S. The low frequency of
reflux in Jamaican children. Pediatr Radiol.
1993;23(8):591–593
35. Anderson PA, Rickwood AM. Features of
primary vesicoureteric reflux detected by
prenatal sonography. Br J Urol. 1991;67(3):
267–271
36. Oliveira EA, Diniz JS, Silva JM, Rabelo EA,
Pontes AK, Souza MF. Features of primary
vesicoureteric reflux detected by investi-
gation of foetal hydronephrosis. Int Urol
Nephrol. 1998;30(5):535–541
37. Koff SA, Wagner TT, Jayanthi VR. The re-
lationship among dysfunctional elimination
syndromes, primary vesicoureteral reflux
and urinary tract infections in children.
J Urol. 1998;160(3 Pt 2):1019–1022
38. Snodgrass W. The impact of treated dys-
functional voiding on the nonsurgical man-
agement of vesicoureteral reflux. J Urol.
1998;160(5):1823–1825
39. Brandström P, Esbjörner E, Herthelius M,
Swerkersson S, Jodal U, Hansson S. The
Swedish reflux trial in children: III. Urinary
tract infection pattern. J Urol. 2010;184(1):
286–291
40. Olbing H, Claësson I, Ebel KD, et al. Renal
scars and parenchymal thinning in chil-
dren with vesicoureteral reflux: a 5-year
report of the International Reflux Study in
Children (European branch). J Urol. 1992;
148(5 Pt 2):1653–1656
41. Shaikh N, Ewing AL, Bhatnagar S, Hoberman
A. Risk of renal scarring in children with
a first urinary tract infection: a system-
atic review. Pediatrics. 2010;126(6):1084–
1091
42. Blane CE, DiPietro MA, Zerin JM, Sedman
AB, Bloom DA. Renal sonography is not
a reliable screening examination for ves-
icoureteral reflux. J Urol. 1993;150(2 Pt 2):
752–755
43. DiPietro MA, Blane CE, Zerin JM. Vesicoure-
teral reflux in older children: concordance
of US and voiding cystourethrographic
findings. Radiology. 1997;205(3):821–822
44. Mahant S, Friedman J, MacArthur C. Renal
ultrasound findings and vesicoureteral
reflux in children hospitalised with urinary
tract infection. Arch Dis Child. 2002;86(6):
419–420
45. Craig JC, Simpson JM, Williams GJ, et al;
Prevention of Recurrent Urinary Tract In-
fection in Children with Vesicoureteric
Reflux and Normal Renal Tracts (PRIVENT)
Investigators. Antibiotic prophylaxis and
recurrent urinary tract infection in chil-
dren. N Engl J Med. 2009;361(18):1748–
1759
46. Montini G, Rigon L, Zucchetta P, et al; IRIS
Group. Prophylaxis after first febrile urinary
tract infection in children? A multicenter,
randomized, controlled, noninferiority trial.
Pediatrics. 2008;122(5):1064–1071
47. Pennesi M, Travan L, Peratoner L, et al;
North East Italy Prophylaxis in VUR study
group. Is antibiotic prophylaxis in children
with vesicoureteral reflux effective in pre-
venting pyelonephritis and renal scars? A
randomized, controlled trial. Pediatrics.
2008;121(6). Available at: www.pediatrics.
org/cgi/content/full/121/6/e1489
48. Roussey-Kesler G, Gadjos V, Idres N, et al.
Antibiotic prophylaxis for the prevention of
recurrent urinary tract infection in chil-
dren with low grade vesicoureteral reflux:
results from a prospective randomized
study. J Urol. 2008;179(2):674–679, discus-
sion 679
49. Camacho V, Estorch M, Fraga G, et al. DMSA
study performed during febrile urinary
tract infection: a predictor of patient out-
come? Eur J Nucl Med Mol Imaging. 2004;31
(6):862–866
50. Craig JC, Irwig LM, Christie J, et al. Vari-
ation in the diagnosis of vesicoureteric
reflux using micturating cystourethrog-
raphy. Pediatr Nephrol. 1997;11(4):455–
459
51. Fernández-Menéndez JM, Málaga S, Matesanz
JL, Solís G, Alonso S, Pérez-Méndez C. Risk
factors in the development of early
technetium-99m dimercaptosuccinic acid re-
nal scintigraphy lesions during first urinary
tract infection in children. Acta Paediatr.
2003;92(1):21–26
52. Hansson S, Dhamey M, Sigström O, et al.
Dimercapto-succinic acid scintigraphy in-
stead of voiding cystourethrography for
infants with urinary tract infection. J Urol.
2004;172(3):1071–1073, discussion 1073–
1074
53. Mahant S, To T, Friedman J. Timing of
voiding cystourethrogram in the in-
vestigation of urinary tract infections in
children. J Pediatr. 2001;139(4):568–571
54. McDonald A, Scranton M, Gillespie R,
Mahajan V, Edwards GA. Voiding cystour-
ethrograms and urinary tract infections:
how long to wait? Pediatrics. 2000;105(4):
E50
55. Oostenbrink R, van der Heijden AJ, Moons
KG, Moll HA. Prediction of vesico-ureteric
reflux in childhood urinary tract infection:
a multivariate approach. Acta Paediatr.
2000;89(7):806–810
e42 CARPENTER et al
56. Pinto KJ. Vesicoureteral reflux in the His-
panic child with urinary tract infection. J
Urol. 2004;171(3):1266–1267
57. Sargent MA, Stringer DA. Voiding cys-
tourethrography in children with urinary
tract infection: the frequency of ves-
icoureteric reflux is independent of the
specialty of the physician requesting the
study. AJR Am J Roentgenol. 1995;164(5):
1237–1241
58. Zamir G, Sakran W, Horowitz Y, Koren A,
Miron D. Urinary tract infection: is
there a need for routine renal ultraso-
nography? Arch Dis Child. 2004;89(5):
466–468
(Continued from first page)
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Diabetes and
Digestive and Kidney Diseases or the National Institutes of Health.
This trial has been registered at www.clinicaltrials.gov (identifier NCT00405704).
www.pediatrics.org/cgi/doi/10.1542/peds.2012-2301
doi:10.1542/peds.2012-2301
Accepted for publication Mar 25, 2013
Address correspondence to: Myra A. Carpenter, PhD, Collaborative Studies Coordinating Center, Department of Biostatistics, CB #8030, 137 E. Franklin St, Suite 203,
University of North Carolina, Chapel Hill, NC 27599-8030. E-mail: myra.carpenter@unc.edu
PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).
Copyright © 2013 by the American Academy of Pediatrics
FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.
FUNDING: Supported by grants U01 DK074059, U01 DK074053, U01 DK074082, U01 DK074064, U01 DK074062, and U01 DK074063 from the National Institute of Diabetes
and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services. The trial was also supported by the Children’s Hospital
of Philadelphia Clinical and Translational Science Award (grant UL1TR000003) from the National Center for Research Resources, now at the National Center for
Advancing Translational Sciences, National Institutes of Health. Funded by the National Institutes of Health (NIH).
ARTICLE
PEDIATRICS Volume 132, Number 1, July 2013 e43
APPENDIX DYSFUNCTIONAL VOIDING (DV) QUESTIONNAIRE
Note: Items 1–10 on the questionnaire are used in the evaluation of BBD.
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